A Trial Of PF-04856884 In Patients With Recurrent Glioblastoma
This study has been withdrawn prior to enrollment.
Information provided by:
First received: October 19, 2010
Last updated: March 10, 2015
Last verified: March 2015
Angiopoietin-2 (Ang-2) is a protein in the body which destabilizes blood vessels and is important in stimulating tumor blood vessels. There is evidence suggesting that Ang-2 may be important for the growth and progression of Glioblastoma multiforme (GBM). PF- 04856884 (CVX-060) is a compound which binds Ang-2 and prevents its activity. The hypothesis is that PF-04856884 will be safe and effective in patients with recurrent Glioblastoma multiforme (GBM).
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||A Phase 2 Trial Of PF-04856884 (CVX-060), A Selective Angiopoietin-2 (Ang-2) Binding CovX-body, In Patients With Recurrent Glioblastoma
Primary Outcome Measures:
- Progression free survival rate at Month 6 (PFS6) defined as the patient progression free status at Month 6. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Corticosteroid doses at baseline and on-study [ Time Frame: 4 months ] [ Designated as safety issue: Yes ]
- Overall Response Rate (ORR) [ Time Frame: 2 years ] [ Designated as safety issue: No ]
- PFS defined as the time from 1st dose of study drug to the 1st documentation of disease progression or death from any cause, whichever comes first. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
- Time to death is defined as the time from first study drug to death due to any cause. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
- Overall survival (OS) defined as the time from first dose of study drug to death due to any cause. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
- OS6 defined as the patient survival status at Month 6. The OS6 rate will be obtained as a Kaplan-Meier estimate of the time to death at Month 6. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
- Immunogenicity determined by measuring anti-PF-04856884 antibodies following therapy [ Time Frame: 4 months ] [ Designated as safety issue: Yes ]
- Dynamic Contrast Enhanced Magnetic Resonance Imaging [DCE-MRI] endpoints to include changes from baseline volume transfer coefficient [Ktrans] and/or the initial area under the contrast agent concentration-time curve [IAUC] or Ki following therapy [ Time Frame: 4 months ] [ Designated as safety issue: No ]
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||January 2013 (Final data collection date for primary outcome measure)
Experimental: Primary Cohort
PF-04856884 at a dose of 15 mg/kg/week
Other Name: CVX-060
Experimental: Exploratory Cohort
PF-04856884 at a dose of 15 mg/kg/week
Other Name: CVX-060
Notification of study being cancelled resulted in update in overall status change from "not yet recruiting" to "withdrawn."
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Tumor eligibility: Primary Cohort: Measurable disease; Exploratory Cohort: Measurable disease as defined above or non-measurable/evaluable disease (eg, progressing non-enhancing lesions).
- Histologically or cytologically confirmed recurrent GBM in 1st or 2nd relapse: Primary Cohort: Recurrence following radiation therapy and temozolomide, less than or equal to 2 prior chemotherapeutic regimens; Exploratory cohort: Prior radiation therapy, temozolomide, and bevacizumab, Recurrence of disease within 2-4 weeks of last bevacizumab dose.
- Stable dose of corticosteroids for greater than or equal to 5 days prior to baseline Magnetic Resonance Imaging (MRI)
- Adequate organ function
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Life expectancy greater than or equal to 12 weeks.
- Patients who have previously received a trial drug containing the core platform antibody (eg, CVX-045, PF-04856884 (CVX-060), CVX-096, PF-05057459 (CVX-241), etc.).
- History of pathologic fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months of therapy.
- Evidence of bleeding diathesis or coagulopathy.
- Major surgical procedure (eg, craniotomy), open biopsy, significant traumatic injury within 28 days prior to therapy or anticipation of need for a major surgical procedure during the course of the trial.
- Minor surgical procedures, fine needle aspiration or core biopsies within 7 days prior to therapy.
- Serious non-healing wound, ulcer, or bone fracture.
- Active gastrointestinal bleeding, as evidenced by either hematemesis, hematochezia, or melena in prior 6 months.
- Hemoptysis >½ teaspoon per day within 1 week of enrollment.
- National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI CTCAE] Grade 3 hemorrhage from any cause <4 weeks prior to enrollment.
- Participation in any investigational drug study within 28 days prior to study therapy.
- Evidence of preexisting uncontrolled hypertension
- Clinically significant cardiovascular disease within the 12 months prior to starting trial treatment
- Prolongation of the QT interval corrected [QTc] interval to >450 msec for men or >470 msec for women.
- History of allergic or anaphylactic reaction to any therapeutic or diagnostic monoclonal antibody or IgG-fusion protein.
Exclusion Criteria Specific for Primary Cohort
- Prior therapy with bevacizumab or other anti-Vascular Endothelial Growth Factor [VEGF] agents for the treatment of GBM.
Exclusion Criteria Specific for Exploratory Cohort
- Patients discontinued from prior bevacizumab or anti-VEGF agents due to toxicity.
- Patients who have failed 2 prior anti-VEGF therapies.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01225510
||Pfizer CT.gov Call Center
No publications provided
||Director, Clinical Trial Disclosure Group, Pfizer, Inc.
History of Changes
|Other Study ID Numbers:
|Study First Received:
||October 19, 2010
||March 10, 2015
||United States: Food and Drug Administration
Keywords provided by Pfizer:
recurrent glioblastoma multiforme (GBM)
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on March 31, 2015
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue